AGR2, a potential prognostic and predictive biomarker and therapeutic to overcome drug resistance in HER2-overexpressing cancer

Abstract excerpt

The development of resistance to HER2-targeted drugs is common. Neratinib, an orally delivered cost effective drug is showing great promise for patients with HER2-overexpressing tumours but, unfortunately, for many the development of resistance is inevitable. In this study spanning novel pairs of cell line models and data from patients’ samples, we used a broad range of methodologies including mass-spectrometry-ba...

Topics

Open a Topic to create a Post that cites this publication.

• Autophagy in Disease and Therapy
• CAR-T cell therapy research
• Endoplasmic Reticulum Stress and Disease
• Glioma Diagnosis and Treatment
• Monoclonal and Polyclonal Antibodies Research
• Neuroblastoma Research and Treatments
• Pancreatic function and diabetes
• Peptidase Inhibition and Analysis

Identifiers and source

Literature Corpus work

c3d7dd04-c05a-55f6-994f-e6d8bb754902

DOI

10.1101/2025.07.23.666253